Trial Profile
Efficacy and safety of 1st-line trastuzumab based treatment, administered for at least 3 years, in patients with HER2-positive metastatic or locally advanced breast cancer – Final results
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2014
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LORHA
- 22 Apr 2014 New trial record